Patents Assigned to Hanmi Pharm. Ind. Co., Ltd.
-
Publication number: 20090238838Abstract: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.Type: ApplicationFiled: November 29, 2007Publication date: September 24, 2009Applicant: HANMI PHARM. IND. CO. LTD.Inventors: Dae Jin Kim, Sung Min Bae, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee, Dae Hae Song, Young Hoon Kim
-
Publication number: 20080124347Abstract: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.Type: ApplicationFiled: May 10, 2007Publication date: May 29, 2008Applicant: HANMI PHARM. IND. CO., LTD.Inventors: Young Min Kim, Dae Jin Kim, Sung Min Bae, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee, Dae Hae Song, Young Hoon Kim
-
Publication number: 20080085862Abstract: The present invention relates to an Natriuretic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an Natriuretic peptide, a non-peptidyl polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The Natriuretic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long-acting formulations of various peptide drugs.Type: ApplicationFiled: May 3, 2007Publication date: April 10, 2008Applicant: HANMI PHARM. IND. CO., LTD.Inventors: Young Kim, Dae Kim, Sung Bae, Chang Lim, Se Kwon, Gwan Lee, Dae Song, Young Kim
-
Publication number: 20060275254Abstract: Disclosed is a novel use of an immunoglobulin Fe fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fe fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fe fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fe fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.Type: ApplicationFiled: November 13, 2004Publication date: December 7, 2006Applicant: Hanmi Pharm. Ind. Co., Ltd.Inventors: Young Kim, Dae Song, Sung Jung, Chang Kim, In Choi, Se Kwon, Gwan Lee
-
Publication number: 20060269553Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.Type: ApplicationFiled: November 13, 2004Publication date: November 30, 2006Applicant: Hanmi Pharm. Ind. Co., Ltd.Inventors: Young Kim, Dae Kim, Sung Bae, Chang Lim, Se Kwon, Gwan Lee
-
Patent number: 5603951Abstract: The present invention relates to a soft capsule composition containing a stable microemulsion concentrate which is more stable and suitable for the preparation of cyclosporin-containing soft capsules. More specifically, the present invention relates to a microemulsion concentrate containing cyclosporin as an active ingredient, dimethylisosorbide as a co-surfactant, one component or a mixture of two or more selected from the group consisting of an esterified compound of fatty acid and primary alcohol, medium chain fatty acid triglyceride and monoglyceride as an oil component, and a surfactant having HLB value of 10 to 17, such as Nikkol HCO-50 or Tween 20, which is suitable for formulation into soft capsules and to a soft capsule composition containing said microemulsion concentrate. In the microemulsion concentrate according to the present invention, cyclosporin, dimethylisosorbide, the oil component and the surfactant are present in the ratio of 1:11-5:1-5:3-6, preferably 1:3-4:1.Type: GrantFiled: April 21, 1995Date of Patent: February 18, 1997Assignee: Hanmi Pharm. Ind. Co., Ltd.Inventor: Jong S. Woo
-
Patent number: 5589455Abstract: The present invention relates to a soft capsule composition containing a stable microemulsion concentrate which is more stable and suitable for the preparation of cyclosporin-containing soft capsules. More specifically, the present invention relates to a microemulsion concentrate containing cyclosporin as an active ingredient, polyethylene glycol as a cosurfactant, one component or a mixture of two or more selected from the group consisting of an esterified compound of fatty acid and primary alcohol, medium chain fatty acid triglyceride and monoglyceride as an oil component, and a surfactant having HLB value of 10 to 17 such as Nikkol HCO-50 or Tween 20, which is suitable for formulation into soft capsules and to a soft capsule composition containing said microemulsion concentrate. In the microemulsion concentrate according to the present invention, cyclosporin, polyethylene glycol, the oil component and the surfactant are present in the ratio of 1:0.1-10:1-10:1-10, preferably 1:0.5-8:2-6:2-8, by weight.Type: GrantFiled: April 21, 1995Date of Patent: December 31, 1996Assignee: Hanmi Pharm. Ind. Co., Ltd.Inventor: Jong S. Woo